Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Receives $28.00 Average Price Target from Analysts

Shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) have earned a consensus rating of “Reduce” from the nine ratings firms that are covering the company, MarketBeat reports. Four analysts have rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $28.00.

Several equities research analysts have commented on the stock. Truist Financial set a $28.00 price target on shares of Fresenius Medical Care AG & Co. KGaA in a report on Monday, January 5th. Wall Street Zen raised shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 20th. Jefferies Financial Group cut shares of Fresenius Medical Care AG & Co. KGaA from a “moderate sell” rating to a “strong sell” rating in a research report on Tuesday, February 24th. Morgan Stanley reissued an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, January 27th. Finally, Weiss Ratings raised shares of Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, February 26th.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

Several hedge funds have recently made changes to their positions in the business. Morgan Stanley increased its stake in shares of Fresenius Medical Care AG & Co. KGaA by 47.2% during the fourth quarter. Morgan Stanley now owns 2,939,839 shares of the company’s stock worth $70,027,000 after buying an additional 942,497 shares during the period. Bank of America Corp DE boosted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 279.7% in the 2nd quarter. Bank of America Corp DE now owns 337,316 shares of the company’s stock valued at $9,637,000 after buying an additional 248,477 shares in the last quarter. ABC Arbitrage SA boosted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 1,136.0% in the 4th quarter. ABC Arbitrage SA now owns 249,800 shares of the company’s stock valued at $5,950,000 after buying an additional 229,589 shares in the last quarter. Integral Health Asset Management LLC grew its position in shares of Fresenius Medical Care AG & Co. KGaA by 44.4% in the 4th quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock valued at $15,483,000 after buying an additional 200,000 shares during the last quarter. Finally, Pzena Investment Management LLC raised its stake in Fresenius Medical Care AG & Co. KGaA by 1.0% during the 3rd quarter. Pzena Investment Management LLC now owns 14,816,852 shares of the company’s stock worth $390,128,000 after acquiring an additional 153,870 shares in the last quarter. Institutional investors and hedge funds own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Trading Down 1.9%

Shares of NYSE FMS opened at $22.97 on Friday. The company has a quick ratio of 0.92, a current ratio of 1.26 and a debt-to-equity ratio of 0.40. The business has a fifty day simple moving average of $23.19 and a two-hundred day simple moving average of $24.35. The firm has a market cap of $13.31 billion, a PE ratio of 12.02, a price-to-earnings-growth ratio of 2.22 and a beta of 0.91. Fresenius Medical Care AG & Co. KGaA has a twelve month low of $20.94 and a twelve month high of $30.46.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last released its quarterly earnings results on Tuesday, February 24th. The company reported $0.83 EPS for the quarter, topping the consensus estimate of $0.67 by $0.16. Fresenius Medical Care AG & Co. KGaA had a return on equity of 8.73% and a net margin of 5.03%.The firm had revenue of $5.95 billion during the quarter, compared to analyst estimates of $4.80 billion. Analysts expect that Fresenius Medical Care AG & Co. KGaA will post 1.51 earnings per share for the current fiscal year.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.